Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children's Hospital Medical Center, Tehran University of Medical Sciences, No. 62, Dr. Qarib's Street, Keshavarz Boulevard, Tehran, 1419433151, Iran.
Probiotics Antimicrob Proteins. 2019 Mar;11(1):158-164. doi: 10.1007/s12602-017-9363-x.
We evaluated the protective effects of probiotic administration as a prophylaxis treatment and immediately after fever onset in increasing the immune response and decreasing the renal scarring in a rat model of acute pyelonephritis. Twenty-four rats were apportioned to three groups. In GI (n = 8), the rats were injected with direct inoculation of Escherichia coli into the right kidney. In GII (n = 8), the rats received a probiotic regimen 1 month before E. coli injection and the probiotic regimen was continued for the next 2 months. In GIII (n = 8), the probiotic regimen was started just after E. coli injection and was continued for 2 months. Technetium-99m-DMSA renal scan, histopathological evaluations, concentrations of CA19-9, IgA, blood urea nitrogen (BUN), and creatinine were assessed 1 and 2 months post-injection. It took an average of 4.2 ± 1.1 h between the injection and onset of fever in GI and GII. In GIII, this period was longer (7.5 ± 1.4). Probiotic administration resulted in reduction of interstitial fibrosis and tubular and glomerular atrophy in GII in all follow-ups. Technetium-99m-DMSA renal scan showed that the right kidney reached near the normal cortical integrity (47%) in GII compared to GI (32%) after 2 months of injection. However, the renal integrity did not improve significantly in GIII (41%). In GII, CA19-9 was lower (p < 0.05), while the levels of serum and fecal IgA were higher (p < 0.05). Administration of the probiotic regimen in the rat model may decrease renal damage in pyelonephritis. In spite of better results in the prophylactic group compared to the treatment group, no strong evidence was found to prove the advantage of its prophylactic application over the treatment administration.
我们评估了益生菌给药作为预防治疗和发热后即刻治疗在增加免疫反应和减少急性肾盂肾炎大鼠模型肾瘢痕形成方面的保护作用。24 只大鼠被分为三组。GI 组（n=8），大鼠右侧肾脏直接接种大肠杆菌。GII 组（n=8），大鼠在大肠杆菌注射前 1 个月接受益生菌方案，并且在接下来的 2 个月继续接受益生菌方案。GIII 组（n=8），益生菌方案在大肠杆菌注射后立即开始，并持续 2 个月。注射后 1 和 2 个月，评估了锝-99m-DMSA 肾扫描、组织病理学评估、CA19-9、IgA、血尿素氮（BUN）和肌酐浓度。GI 和 GII 中，从注射到发热的平均时间为 4.2±1.1 小时。在 GIII 中，这段时间更长（7.5±1.4）。在所有随访中，益生菌给药导致 GII 中间质纤维化和肾小管和肾小球萎缩减少。锝-99m-DMSA 肾扫描显示，与 GI 相比（32%），在注射后 2 个月，GII 中右肾接近正常皮质完整性（47%）。然而，GIII 中肾完整性没有显著改善（41%）。GII 中 CA19-9 较低（p<0.05），而血清和粪便 IgA 水平较高（p<0.05）。在肾盂肾炎大鼠模型中，益生菌方案的给药可能会减轻肾脏损伤。尽管预防组的结果明显优于治疗组，但没有强有力的证据证明其预防应用优于治疗给药。
